LncRNA SLC8A1‐AS1 protects against myocardial damage through activation of cGMP‐PKG signaling pathway by inhibiting SLC8A1 in mice models of myocardial infarction

Abstract

Extensive investigations into long noncoding RNAs (lncRNAs) in various diseases and cancers, including acute myocardial infarction (AMI) have been conducted. The current study aimed to investigate the role of lncRNA solute carrier family 8 member A1 antisense RNA 1 (SLC8A1‐AS1) in myocardial damage by targeting solute carrier family 8 member A1 (SLC8A1) via cyclic guanosine 3′,5′‐monophosphate‐protein kinase G (cGMP‐PKG) signaling pathway in AMI mouse models. Differentially expressed lncRNA in AMI were initially screened and target relationship between lncRNA SLC8A1‐AS1 and SLC8A1 was then verified. Infarct size, levels of inflammatory factors, biochemical indicators, and the positive expression of the SLC8A1 protein in AMI were subsequently determined. The expression of SLC8A1‐AS1, SLC8A1, PKG1, PKG2, atrial natriuretic peptide, and brain natriuretic peptide was detected to assess the effect of SLC8A1‐AS1 on SLC8A1 and cGMP‐PKG. The respective contents of superoxide dismutase, lactate dehydrogenase (LDH), and malondialdehyde (MDA) were detected accordingly. Microarray data GSE66360 provided evidence indicating that SLC8A1‐AS1 was poorly expressed in AMI. SLC8A1 was verified to be a target gene of lncRNA SLC8A1‐AS1. SLC8A1‐AS1 upregulation decreased levels of left ventricular end‐systolic diameter, −dp/ dt max, interleukin 1β (IL‐1β), IL‐6, transforming growth factor α, nitric oxide, inducible nitric‐oxide synthase, endothelial nitric‐oxide synthase, infarct size, LDH activity and MDA content, and increased IL‐10, left ventricular end‐diastolic pressure and + dp/ dt max. Furthermore, the overexpression of SLC8A1‐AS1 was noted to elicit an inhibitory effect on the cGMP‐PKG signaling pathway via SLC8A1. In conclusion, lncRNA SLC8A1‐AS1, by downregulating SLC8A1 and activating the cGMP‐PKG signaling pathway, was observed to alleviate myocardial damage, inhibit the release of proinflammatory factors and reduce infarct size, ultimately protecting against myocardial damage.